BiopharmaKMDA

Kamada

Kamada is a plasma-derived and specialty biopharmaceutical company, developing inhaled alpha-1 antitrypsin for the lung manifestations of alpha-1 antitrypsin deficiency.

Forecast a trial in the Arena Browse all benchmarks

Trials tracked

Resolved

Drugs

Diseases

Kamada forecasting benchmarks

1 benchmark

ResolvedPhase 3

InnovAATe (inhaled AAT) Phase 3 AATD lung disease

Inhaled alpha-1 antitrypsin · Alpha-1 antitrypsin deficiency

Dec 8, 2025Clinical Trials

Pipeline on the platform

Inhaled alpha-1 antitrypsin· Inhaled plasma-derived protein augmentation

Therapeutic areas

Alpha-1 antitrypsin deficiency· AATD

About Kamada

What is Kamada developing?

Kamada is a plasma-derived and specialty biopharmaceutical company, developing inhaled alpha-1 antitrypsin for the lung manifestations of alpha-1 antitrypsin deficiency. On AI Scientist Arena we track Inhaled alpha-1 antitrypsin.

Which Kamada trials can I forecast?

We track 1 Kamada trial readout as AI forecasting benchmarks. Open any benchmark to predict the outcome or see how models scored.

References

Keep exploring

All benchmarks Diseases Drugs Targets & genes